Eli Lilly is moving closer to bringing its experimental weight loss pill, orforglipron, to market after releasing positive results from its latest phase 3 clinical trial. The study, called Attain-2, tested the once-daily pill in people who are overweight or obese and also have Type 2 diabetes—a group often harder to treat. The trial found
Novo Nordisk’s popular weight-loss drug Wegovy has just received a new approval from the U.S. Food and Drug Administration (FDA)—this time for treating a serious liver condition called metabolic dysfunction-associated steatohepatitis (MASH). This marks Wegovy’s third approved use, following its approvals for obesity and reducing cardiovascular risk. MASH, once known as NASH, is caused by
The availability of COVID-19 vaccines for young children in the U.S. could shrink this fall as the Food and Drug Administration (FDA) considers ending the emergency use authorization (EUA) for Pfizer-BioNTech’s vaccine in kids ages 6 months to 4 years. Pfizer says it is in discussions with the FDA and has asked to keep the
The FDA has approved a safer dosing schedule for Eli Lilly’s Alzheimer’s drug, Kisunla, which could make it more appealing to doctors and patients. The updated schedule reduces the risk of a serious side effect called ARIA-E—brain swelling caused by anti-amyloid drugs. Originally, Kisunla was given in higher doses early on. Now, the drug will
La Food and Drug Administration (FDA) des États-Unis a approuvé Nucala (mépolizumab) comme traitement d’appoint pour les adultes atteints de maladie pulmonaire obstructive chronique (MPOC) qui continuent de présenter des exacerbations malgré une triple thérapie inhalée. Nucala est le premier médicament biologique spécifiquement approuvé pour les patients MPOC présentant un « phénotype éosinophilique » — un groupe
Canada is increasing its supply of bird flu (avian influenza) vaccines, following similar actions in the U.S. and U.K. The Public Health Agency of Canada (PHAC) secured 500,000 doses of GSK’s Arepanrix H5N1 vaccine, which is based on proven flu shot technology. Canada’s health regulator has approved a change in the vaccine strain, ensuring it
The FDA has approved Novo Nordisk’s drug Ozempic for a new use: reducing the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease (CKD). This approval is significant because Ozempic is now the first drug in its class (GLP-1 receptor agonists) with
Arrowhead Pharmaceuticals announced positive results from its Phase 3 PALISADE study on plozasiran, a new drug for treating familial chylomicronemia syndrome (FCS). FCS is a rare genetic condition that causes extremely high triglyceride levels, leading to serious health issues like acute pancreatitis. Currently, there are no approved treatments for FCS in the United States or
Merck & Co.’s new vaccine, CAPVAXIVE (V116), has been approved by the FDA for preventing invasive diseases and pneumonia in adults 18 and older caused by specific strains of the bacteria Streptococcus pneumoniae. This vaccine is particularly aimed at protecting adults over 50 from around 84% of invasive pneumococcal diseases. In several studies, CAPVAXIVE showed
The US Food and Drug Administration (FDA) has granted approval to GlaxoSmithKline (GSK) for Arexvy, the world’s first vaccine designed to protect older adults against respiratory syncytial virus (RSV). RSV is a common respiratory virus that can cause serious illness, particularly in adults over 65 years of age, and in infants and young children. It
